Consensus 8c. Cuts FY25 revenue view to $807M-$823M from $840M-$860M, consensus $846.39M. Cuts FY25 adjusted EBITDA view to $19M-$27M from $25M-$35M. Updated guidance reflects Q1 results and the current business outlook.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics reports Q1 adjusted EPS (3c), consensus (5c)
- Myriad Genetics announces survey results on depression, anxiety
- MYGN Upcoming Earnings Report: What to Expect?
- Myriad says GeneSight Psychotropic Test led to fewer hospitalizations in study
- Myriad Genetics price target lowered to $9 from $11 at BofA
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue